PharmGKB summary: very important pharmacogene information for RYR1

被引：11

作者：

Alvarellos, Maria L. ^{[1
]}

Krauss, Ronald M. ^{[3
,4
]}

Wilke, Russell A. ^{[5
,6
]}

Altman, Russ B. ^{[1
,2
]}

Klein, Teri E. ^{[1
]}

机构：

[1] Stanford Univ, Dept Genet, Stanford, CA 94305 USA

[2] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA

[3] Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA

[4] UCSF, Oakland, CA USA

[5] Univ N Dakota, Dept Med, Fargo, ND USA

[6] Sanford Healthcare, IMAGENET, Sioux Falls, SD USA

来源：

PHARMACOGENETICS AND GENOMICS | 2016年 / 26卷 / 03期

关键词：

CENTRAL CORE DISEASE; MALIGNANT HYPERTHERMIA MUTATION; MUSCLE SARCOPLASMIC-RETICULUM; RYANODINE RECEPTOR MUTATIONS; CALCIUM-RELEASE CHANNEL; SKELETAL-MUSCLE; GENETIC RISK; MYOTUBES; CA2+; 4-CHLORO-M-CRESOL;

D O I：

10.1097/FPC.0000000000000198

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

[No abstract available]

引用

页码：138 / 144

页数：7

共 87 条

[1] Phenotype Standardization for Statin-Induced Myotoxicity [J].

Alfirevic, A. ;

Neely, D. ;

Armitage, J. ;

Chinoy, H. ;

Cooper, R. G. ;

Laaksonen, R. ;

Carr, D. F. ;

Bloch, K. M. ;

Fahy, J. ;

Hanson, A. ;

Yue, Q-Y ;

Wadelius, M. ;

Maitland-van der Zee, A. H. ;

Voora, D. ;

Psaty, B. M. ;

Palmer, C. N. A. ;

Pirmohamed, M. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (04) :470-476

[2] Noninvasive testing for malignant hyperthermia susceptibility [J].

Allen, PD ;

López, JR .

ANESTHESIOLOGY, 2002, 97 (05) :1045-1046

[3] An integrated map of genetic variation from 1,092 human genomes [J].

Altshuler, David M. ;

Durbin, Richard M. ;

Abecasis, Goncalo R. ;

Bentley, David R. ;

Chakravarti, Aravinda ;

Clark, Andrew G. ;

Donnelly, Peter ;

Eichler, Evan E. ;

Flicek, Paul ;

Gabriel, Stacey B. ;

Gibbs, Richard A. ;

Green, Eric D. ;

Hurles, Matthew E. ;

Knoppers, Bartha M. ;

Korbel, Jan O. ;

Lander, Eric S. ;

Lee, Charles ;

Lehrach, Hans ;

Mardis, Elaine R. ;

Marth, Gabor T. ;

McVean, Gil A. ;

Nickerson, Deborah A. ;

Schmidt, Jeanette P. ;

Sherry, Stephen T. ;

Wang, Jun ;

Wilson, Richard K. ;

Gibbs, Richard A. ;

Dinh, Huyen ;

Kovar, Christie ;

Lee, Sandra ;

Lewis, Lora ;

Muzny, Donna ;

Reid, Jeff ;

Wang, Min ;

Wang, Jun ;

Fang, Xiaodong ;

Guo, Xiaosen ;

Jian, Min ;

Jiang, Hui ;

Jin, Xin ;

Li, Guoqing ;

Li, Jingxiang ;

Li, Yingrui ;

Li, Zhuo ;

Liu, Xiao ;

Lu, Yao ;

Ma, Xuedi ;

Su, Zhe ;

Tai, Shuaishuai ;

Tang, Meifang .

NATURE, 2012, 491 (7422) :56-65

[4] PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics [J].

Alvarellos, Maria L. ;

McDonagh, Ellen M. ;

Patel, Sephalie ;

McLeod, Howard L. ;

Altman, Russ B. ;

Klein, Teri E. .

PHARMACOGENETICS AND GENOMICS, 2015, 25 (12) :622-630

[5] Ryanodine receptor calcium release channels: lessons from structure-function studies [J].

Amador, Fernando J. ;

Stathopulos, Peter B. ;

Enomoto, Masahiro ;

Ikura, Mitsuhiko .

FEBS JOURNAL, 2013, 280 (21) :5456-5470

[6]

[Anonymous], DAT SINGL NUCL POL D

[7]

Appiah-Ankam J., 2004, CONTIN ED ANAESTH CR, V4, P2, DOI [DOI 10.1093/BJACEACCP/MKH002, 10.1093/bjaceaccp/mkh002]

[8] Functional effects of central core disease mutations in the cytoplasmic region of the skeletal muscle ryanodine receptor [J].

Avila, G ;

Dirksen, RT .

JOURNAL OF GENERAL PHYSIOLOGY, 2001, 118 (03) :277-290

[9] Dantrolene-Induced Inhibition of Skeletal L-Type Ca2+ Current Requires RyR1 Expression [J].

Bannister, R. A. .

BIOMED RESEARCH INTERNATIONAL, 2013, 2013

[10] Contractile impairment and structural alterations of skeletal muscles from knockout mice lacking type 1 and type 3 ryanodine receptors [J].

Barone, V ;

Bertocchini, F ;

Bottinelli, R ;

Protasi, F ;

Allen, PD ;

Armstrong, CF ;

Reggiani, C ;

Sorrentino, V .

FEBS LETTERS, 1998, 422 (02) :160-164

← 1 2 3 4 5 6 7 8 9 →